预约演示

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

2023-03-13

临床结果疫苗突破性疗法临床2期优先审批

Merck & Co (Merck) – known as MSD outside the US and Canada – has reported positive results from a phase 2/3 study of its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with chemotherapy for certain malignant pleural mesothelioma patients.

Merck & ComeMercklioma is a type of cancer that starts in the linings of certain parts of the body, with new cases numbering 30PD-1 worldwidKeytruda0.pembrolizumab malignant pleural mesothelioma

Malignant mesotheliomawhich developscancere lining of the lungs, is the most common form of the disease, accounting for about 75% of all cases.

Pleural mesotheliomaesothelioma is a rapidly progressing cancer that develops in the lining of the lungs and has a poor prognosis,” explained Dr Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories.

TMalignant pleural mesotheliomaOTE-483 trial was sponsorecancerconducted by the Canadian Cancer Trials Group (CCTG) in collaboration with investigators in Italy and France.Merck Research Laboratories

At the final analysis of the study, Keytruda plus chemotherapy showed a statistically sigCancernt and clinically meaningful improvement in overall survival compared to chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

The safety profile of the combinatioKeytrudaso consistent with previously reported studies, Merck reported.unresectable advanced or metastatic malignant pleural mesothelioma

“Patients are in need of new treatments that can improve survival outcomes, and these positiMercksults support the potential of Keytruda in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma,” Barr said.

Dr Quincy Chu, CCTG’s study chair of the trial, added: “The results from the trial have the potential to make a difference for pKeytrudawith this disease who have had limited treatment options available to them.”malignant mesothelioma

Merck said it pCCTG to share full details from the trial at an upcoming medical meeting.

Merckuda’s combination with platinum-based chemotherapy has already become a standard of care in certain metastatic non-small cell lung cancer patients.

Keytruda was granted breakthrough therapy designation in the US in February, in combination with Merck anmetastatic non-small cell lung cancersed mRNA cancer vaccine, as an additional treatment for high-risk melanoma patients.

This was based on positive results from a phase 2b trial in which the combination reduced risk ofMerckrrence or death by 44% compared with Merck’s anticancertherapy alone.high-risk melanoma

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构